In quiet debut, Alzheimer's drug finds questions, skepticism

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed

Related Keywords

Rhode Island ,United States ,Boston ,Massachusetts ,Dallas ,Texas ,Washington ,Los Angeles ,Stephen Salloway ,Maha Radhakrishnan ,Brendan Kelley ,Salim Syed ,Wendy Van Fossen ,Neurology Center ,Ut Southwestern Medical Center ,Japan Eisai Co ,Drug Administration ,Cleveland Clinic ,Mass General Brigham ,Mizuho Securities United ,Medical Center ,Van Fossen ,Biogen Chief Medical Officer ,Zaldy Tan ,Medicare Advantage ,Business ,Health ,Iagnosis And Treatment ,Overnment Regulations ,Overnment And Politics ,Science ,Ealthcare Industry Regulation ,Ndustry Regulation ,Overnment Business And Finance ,Medication ,Medicare ,Overnment Funded Health Insurance ,Overnment Programs ,Edicare Health Plans ,Personal Health Insurance ,Personal Insurance ,Personal Finance ,Ccess To Health Care ,Alzheimers Disease ,Neurological Disorders ,Iseases And Conditions ,Seniors Health ,Drug Approvals ,Product Approvals ,New Products And Services ,Products And Services ,Corporate News ,